Navigation Links
Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM

OXFORD, England, April 24 /PRNewswire/ -- PharmaVentures Ltd, announced today that it has been engaged by Merck & Co, Inc. to advise and assist in divesting its world class research centre, the IRBM, located near Rome, Italy. The engagement will utilise PharmaVentures' pharmaceutical transactions experience in the healthcare and investment business sectors. The IRBM is an integrated, state-of-the-art small molecule and biological discovery centre. IRBM has an outstanding record of drug discovery including Isentress(R), the first approved HIV integrase inhibitor and winner of the Prix Galien USA 2008 award for the best pharmaceutical agent. The centre has received significant investment since 2000 and is staffed with exceptional, experienced pharmaceutical scientists.

Dr Fintan Walton, CEO, PharmaVentures commented, "This research centre is a rare opportunity for a pharmaceutical company or contract research organisation to expand its operations and gain access to one of the world's foremost research centres."

A leading results driven organisation, PharmaVentures ( assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored consulting and transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals(R) range of intelligence products which include analysis tools and reports. An innovative business, PharmaVentures additionally provides industry insight, business reviews and deal making trends through the world's first online pharmaceutical television channel Now in its 17th year, PharmaVentures is based in Oxford, UK, employs over 50 people mostly educated to PhD or above. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.

    For further information please contact:
    Lisa Holloway

SOURCE PharmaVentures Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
2. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
3. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
4. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
5. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
6. Merck & Co., Inc. Named Keynote Sponsor For Diversity Alliance For Sciences Inaugural Conference
7. New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
8. BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance
9. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
10. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
11. Merck Serono Named as a Top Employer by Science Magazine
Post Your Comments:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):